Skip to main content
ILYANG PHARMACEUTICAL CO.,LTD logo

ILYANG PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 007570 ISIN · KR7007570005 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2024-08-02 Director's Dealing
Country KR South Korea
Listing KO 007570

About ILYANG PHARMACEUTICAL CO.,LTD

https://www.ilyang.co.kr

Ilyang Pharmaceutical, established in 1946, is a research-oriented company that develops and manufactures a diverse portfolio of pharmaceutical products. The company focuses on developing new chemical entities (NCEs) and produces a range of medicines targeting digestive, respiratory, and circulatory system disorders, as well as neoplasms and infectious diseases. Key developments include 'Ilaprazole' (Noltec), a proton pump inhibitor for acid-related disorders, and 'Supect' (Radotinib), a treatment for chronic myeloid leukemia. Its product line also encompasses general drugs, antibiotics, anti-inflammatory agents, nutritional supplements, and well-established consumer health brands like the digestive aid 'NORUMO' and the nutritional drink 'Wonbi-D'.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure document required by the Financial Supervisory Service (FSS) in South Korea when a company executive or major shareholder changes their shareholding position. This falls under the category of 'Director's Dealing' (DIRS), as it details the personal share transactions (장내매수 - open market purchases) by a company executive (Jung Yu-seok, CEO).
2024-08-02 Korean
최대주주등소유주식변동신고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Change in Shareholding by Major Shareholders' (최대주주등소유주식변동신고서) for Il-Yang Pharmaceutical. It details specific share purchases by a major shareholder (Jung Yoo-seok) and provides a summary of the total shareholding changes for the major shareholders group. This type of filing is a standard regulatory disclosure regarding significant share ownership changes, which falls under the 'Major Shareholding Notification' category.
2024-08-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Jung Yu-seok) of ILYANG PHARMACEUTICAL CO., LTD. This type of filing is a standard regulatory requirement for insiders to disclose their share transactions (insider trading). Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2024-07-31 Korean
최대주주등소유주식변동신고서
Director's Dealing Classification · 100% confidence The document is a 'Report of Changes in Shareholding by Major Shareholders and Related Parties' (최대주주등소유주식변동신고서) filed by Il-Yang Pharmaceutical. It details specific share transactions (purchases) made by individuals identified as major shareholders or related parties (친인척). This type of filing is a standard regulatory requirement for reporting insider/major shareholder transactions, which falls under the 'Director's Dealing' (DIRS) category in the provided schema, as it tracks personal share transactions by company-affiliated individuals.
2024-07-31 Korean
투자유의안내 (일양약품1우선주 관리종목지정 우려 예고)
Regulatory Filings Classification · 100% confidence The document is a formal notice from the Korea Exchange (KRX) regarding the potential designation of Il-Yang Pharmaceutical's preferred stock as a 'managed issue' due to low trading volume. This is a regulatory announcement concerning stock market status and compliance, which does not fit into specific categories like earnings, dividends, or M&A. Therefore, it is classified as a general regulatory filing.
2024-06-21 Korean
투자유의안내 (일양약품1우선주 관리종목지정 우려 예고)
Regulatory Filings Classification · 100% confidence The document is a formal notice from the Korea Exchange (KRX) regarding the potential designation of a specific stock (Il-Yang Pharmaceutical 1st Preferred Shares) as a 'managed issue' due to low trading volume. This is a regulatory announcement concerning market status and trading conditions, which does not fit into specific categories like earnings, dividends, or M&A. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a general regulatory announcement.
2024-06-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.